| NCT ID | NCT05915208 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Alabama at Birmingham |
| Condition | Histiocytosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 6,000 participants |
| Start Date | 2022-09-01 |
| Primary Completion | 2027-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 6,000 participants in total. It began in 2022-09-01 with a primary completion date of 2027-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the study is to describe the burden of chronic health conditions, psychological dysfunction, chronic pain, healthcare utilization, worse health-related quality of life, overall mortality, and cause-specific mortality among individuals with histiocytic disorders
Eligibility Criteria
Inclusion Criteria: * diagnosis of histiocytic disorder at any age 1. Langerhans cell histiocytosis, 2. Erdheim-Chester disease, 3. Rosai-Dorfman disease, 4. Xanthogranuloma, 5. Mixed histiocytosis 6. Malignant histiocytosis (Histiocytic sarcoma, langerhans cell sarcoma, interdigitating cell sarcoma) 7. Hemophagocytic lymphohistiocytosis Exclusion Criteria: * None
Contact & Investigator
Gaurav Goyal, MD
PRINCIPAL INVESTIGATOR
University of Alabama at Birmingham
Frequently Asked Questions
Who can join the NCT05915208 clinical trial?
This trial is open to participants of all sexes, aged 0 Years or older, up to 89 Years, studying Histiocytosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05915208 currently recruiting?
Yes, NCT05915208 is actively recruiting participants. Contact the research team at histio@uabmc.edu for enrollment information.
Where is the NCT05915208 trial being conducted?
This trial is being conducted at Birmingham, United States.
Who is sponsoring the NCT05915208 clinical trial?
NCT05915208 is sponsored by University of Alabama at Birmingham. The principal investigator is Gaurav Goyal, MD at University of Alabama at Birmingham. The trial plans to enroll 6,000 participants.